Division of Pharmaceutical Technology, P.O. Box 56, FI-00014, University of Helsinki, Finland.
J Control Release. 2011 Dec 20;156(3):390-7. doi: 10.1016/j.jconrel.2011.07.016. Epub 2011 Jul 23.
Nanosizing is an advanced approach to overcome poor aqueous solubility of active pharmaceutical ingredients. One main problem in pharmaceutical nanotechnology is maintaining of the morphology of the nanometer sized particles during processing and storage to make sure the formulation behaves as originally planned. Here, a genetically engineered hydrophobin fusion protein, where the hydrophobin (HFBI) was coupled with two cellulose binding domains (CBDs), was employed in order to facilitate drug nanoparticle binding to nanofibrillar cellulose (NFC). The nanofibrillar matrix provides protection for the nanoparticles during the formulation process and storage. It was demonstrated that by enclosing the functionalized protein coated itraconazole nanoparticles to the external nanofibrillar cellulose matrix notably increased their storage stability. In a suspension with cellulose nanofibrils, nanoparticles around 100 nm could be stored for more than ten months when the specific cellulose binding domain was fused to the hydrophobin. Also freeze-dried particles in the cellulose nanofibrils matrix were preserved without major changes in their morphology. In addition, as a consequence of formation of the immobilized nanodispersion, dissolution rate of itraconazole was increased significantly, which also enhanced the in vivo performance of the drug.
纳米化是克服活性药物成分水溶性差的一种先进方法。药物纳米技术的一个主要问题是在加工和储存过程中保持纳米颗粒的形态,以确保制剂按原计划进行。在这里,使用了一种经过基因工程改造的疏水蛋白融合蛋白,其中疏水蛋白 (HFBI) 与两个纤维素结合结构域 (CBD) 偶联,以促进药物纳米颗粒与纳米原纤化纤维素 (NFC) 的结合。纳米原纤基质在制剂过程和储存期间为纳米颗粒提供保护。结果表明,通过将功能化的蛋白包裹的酮康唑纳米颗粒封闭到外部纳米原纤纤维素基质中,可以显著提高它们的储存稳定性。在含有纤维素纳米纤维的悬浮液中,当特定的纤维素结合结构域与疏水蛋白融合时,粒径约为 100nm 的纳米颗粒可以储存超过十个月。此外,在纤维素纳米纤维基质中的冷冻干燥颗粒也得以保存,其形态没有发生重大变化。此外,由于形成固定化纳米分散体,酮康唑的溶解速率显著提高,这也增强了药物的体内性能。